Summarize this content to 2000 words in 6 paragraphs
Oisín Biotechnologies, a Seattle-based startup focused on treating aging-related diseases, raised the first close of a $15 million Series A round.
The company is developing preclinical therapies to eliminate unwanted fat cells and build muscle mass to address frailty.
Oisín was founded in 2016 by Matthew Scholz, Oisín’s CEO, along with John Lewis, chief science officer, and Gary Hudson, chairman. Scholz is also CEO of OncoSenX, which spun out of Oisín in 2018 and is studying the treatment of solid tumors.
AbbVie Ventures led the first close.
Editor’s note: This story was updated to reflect that the company raised its first close of the Series A round.
